Emergency Briefing: “The Great Reset”
By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. Jeff Brown, a member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive.
Click here to see this emergency briefing before i

RARE Insider Trading (Ultragenyx Pharmaceutical)

Insider Ownership Percentage: 8.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $30,906,784.24

Ultragenyx Pharmaceutical Insider Trading History Chart

Ultragenyx Pharmaceutical Share Price & Price History

$103.48
▼ -3.07 (-2.88%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Man Who Predicted March 2020 Crash Says 2021 Is The Time
If you've got money invested in the stock market, but are confused as to what to do next...This is the can't-miss interview of 2021...
Learn more here!

Ultragenyx Pharmaceutical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2021Theodore Alan HuizengaSVPSell3,000$120.69$362,070.00  
3/1/2021Emil D KakkisCEOSell30,000$141.80$4,254,000.00596,941  
3/1/2021John Richard PinionInsiderSell6,198$138.17$856,377.6651,799  
3/1/2021Theodore Alan HuizengaSVPSell732$138.17$101,140.4417,276  
3/1/2021Thomas Richard KassbergEVPSell4,572$138.17$631,713.24106,978  
2/19/2021William AliskiDirectorSell7,500$149.01$1,117,575.0073,204  
1/30/2021Camille L. BedrosianEVPSell2,243$140.36$314,827.48  
1/7/2021Theodore Alan HuizengaSVPSell4,000$140.65$562,600.0020,436  
1/4/2021Emil D KakkisCEOSell30,000$136.90$4,107,000.00
10/30/2020Karah Herdman ParschauerEVPSell9,903$100.12$991,488.3633,871  
10/28/2020Karah Herdman ParschauerEVPSell97$100.00$9,700.0024,065  
10/14/2020Camille L. BedrosianEVPSell262$88.00$23,056.00  
10/14/2020Theodore Alan HuizengaSVPSell146$87.98$12,845.08  
10/12/2020John Richard PinionInsiderSell2,780$94.47$262,626.60  
10/8/2020Karah Herdman ParschauerEVPSell10,000$95.00$950,000.0034,293  
10/6/2020Karah Herdman ParschauerEVPSell10,000$90.00$900,000.0034,293  
9/23/2020Karah Herdman ParschauerEVPSell10,000$85.00$850,000.0034,293  
9/1/2020Emil D. KakkisCEOSell30,000$82.63$2,478,900.00  
8/17/2020Karah Herdman ParschauerEVPSell12,370$88.43$1,093,879.1036,663  
8/17/2020Shalini SharpCFOSell14,378$88.40$1,271,015.20100,747  
8/10/2020Clay B SiegallDirectorSell11,346$85.01$964,523.4618,204  
8/7/2020Clay B SiegallDirectorSell23,404$85.55$2,002,212.2018,204  
7/13/2020Emil D. KakkisCEOSell40,000$85.35$3,414,000.00  
7/8/2020Theodore Alan HuizengaSVPSell2,638$91.00$240,058.0016,582  
7/6/2020Matthew K FustDirectorSell6,181$90.00$556,290.0019,731  
7/1/2020Matthew K FustDirectorSell5,000$85.00$425,000.0018,550  
7/1/2020Theodore Alan HuizengaSVPSell2,611$81.00$211,491.0017,220  
6/3/2020Shalini SharpCFOSell10,234$74.23$759,669.82111,442  
5/26/2020Theodore Alan HuizengaSVPSell260$74.93$19,481.8018,591  
5/19/2020Shalini SharpCFOSell7,128$73.32$522,624.96122,929  
5/18/2020Karah Herdman ParschauerEVPSell2,722$74.72$203,387.84  
5/18/2020Matthew K. FustDirectorSell1,875$75.00$140,625.0055,424  
5/15/2020Theodore Alan HuizengaSVPSell2,461$71.00$174,731.0018,719  
4/22/2020Matthew K. FustDirectorSell1,875$65.00$121,875.00  
1/14/2020Theodore Alan HuizengaSVPSell1,000$61.00$61,000.00  
9/11/2019Emil D KakkisCEOBuy5,000$43.63$218,150.00472,479  
6/24/2019Karah Herdman ParschauerEVPSell1,226$61.50$75,399.00  
6/21/2019Karah Herdman ParschauerEVPSell1,489$63.01$93,821.89  
4/29/2019Karah Herdman ParschauerEVPSell468$68.30$31,964.40  
3/18/2019Shalini SharpCFOSell14,800$70.00$1,036,000.00  
12/7/2018William AliskiDirectorSell6,000$49.69$298,140.0072,610  
11/8/2018William AliskiDirectorSell6,000$55.67$334,020.0072,610  
10/8/2018William AliskiDirectorSell19,550$72.49$1,417,179.5072,610  
9/25/2018Shalini SharpCFOSell6,700$90.07$603,469.0056,828  
8/21/2018Karah Herdman ParschauerEVPSell5,000$78.53$392,650.00  
8/8/2018William AliskiDirectorSell3,750$76.66$287,475.0072,610  
6/21/2018Karah Herdman ParschauerEVPSell1,226$82.77$101,476.02  
6/15/2018Theodore Alan HuizengaVPSell955$83.70$79,933.5012,895  
6/13/2018Theodore Alan HuizengaVPSell1,338$76.97$102,985.86  
6/7/2018Shalini SharpCFOSell6,700$80.07$536,469.0060,178  
5/30/2018Matthew K FustDirectorSell6,319$72.00$454,968.008,750  
5/30/2018Shalini SharpCFOSell13,000$70.17$912,210.0070,174  
5/10/2018Karah Herdman ParschauerEVPSell1,465$60.00$87,900.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Institutional Buying and Selling by Quarter

Ultragenyx Pharmaceutical Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/5/2021Pacer Advisors Inc.609$69K0.0%-32.7%0.001%
3/12/2021DekaBank Deutsche Girozentrale16,910$2.48M0.0%-8.3%0.025%
3/8/2021Dimensional Fund Advisors LP346,541$47.98M0.0%-6.2%0.518%
3/2/2021Norges Bank559,443$77.44M0.0%N/A0.836%
3/1/2021UBS Asset Management Americas Inc.68,401$9.47M0.0%+4.7%0.102%
2/25/2021Dimensional Fund Advisors LP346,541$47.98M0.0%-6.2%0.518%
2/25/2021Hsbc Holdings PLC9,962$1.40M0.0%+89.3%0.015%
2/24/2021Virtu Financial LLC14,202$1.97M0.2%N/A0.021%
2/23/2021Pier 88 Investment Partners LLC3,320$0.46M0.1%-71.0%0.005%
2/23/2021WCM Investment Management LLC71,729$9.93M0.0%+5.8%0.107%
2/23/2021Principal Financial Group Inc.28,360$3.93M0.0%+35.1%0.042%
2/19/2021JPMorgan Chase & Co.231,430$32.04M0.0%+24.4%0.379%
2/19/2021AtonRa Partners17,646$2.44M1.2%N/A0.029%
2/18/2021Truist Financial Corp10,618$1.47M0.0%+102.1%0.017%
2/17/2021Twinbeech Capital LP6,830$0.95M0.2%N/A0.011%
2/17/2021Voloridge Investment Management LLC11,585$1.60M0.0%+8.5%0.019%
2/17/2021Castleark Management LLC18,945$2.62M0.1%-77.2%0.031%
2/17/2021Cim Investment Mangement Inc.1,517$0.21M0.1%N/A0.002%
2/16/2021Glenmede Trust Co. NA3,545$0.49M0.0%+11.7%0.006%
2/16/2021Morgan Stanley251,328$34.79M0.0%+106.9%0.412%
2/16/2021Baker BROS. Advisors LP444,444$61.52M0.2%N/A0.728%
2/16/2021Paloma Partners Management Co4,182$0.58M0.0%N/A0.007%
2/16/2021Tudor Investment Corp Et Al17,712$2.45M0.1%+10.8%0.029%
2/16/2021Nuveen Asset Management LLC413,991$57.31M0.0%+7.7%0.678%
2/16/2021Captrust Financial Advisors541$75K0.0%N/A0.001%
2/16/2021WCM Investment Management LLC71,729$9.93M0.0%+5.8%0.118%
2/16/2021Guggenheim Capital LLC18,379$2.54M0.0%-42.3%0.030%
2/16/2021Price T Rowe Associates Inc. MD9,470,492$1.31B0.1%+13.4%15.514%
2/16/2021Virginia Retirement Systems ET AL8,600$1.19M0.0%+126.3%0.014%
2/16/2021Engineers Gate Manager LP10,677$1.48M0.1%N/A0.017%
2/16/2021Capital International Ltd.79,742$11.04M0.6%+1.3%0.131%
2/16/2021Charles Schwab Investment Management Inc.543,274$75.21M0.0%+10.4%0.890%
2/13/2021American International Group Inc.38,394$5.32M0.0%+11.6%0.063%
2/12/2021Capital Impact Advisors LLC25,582$3.54M0.9%-49.4%0.042%
2/12/2021Federated Hermes Inc.4,280,528$592.55M1.2%+4.5%7.012%
2/12/2021LPL Financial LLC2,667$0.37M0.0%N/A0.004%
2/12/2021Amalgamated Bank9,773$1.35M0.1%+9.3%0.016%
2/12/2021Public Employees Retirement System of Ohio1,210$0.17M0.0%-11.5%0.002%
2/12/2021The Manufacturers Life Insurance Company37,202$5.15M0.0%+12.3%0.061%
2/12/2021Advisory Research Inc.4,403$0.61M0.0%-65.2%0.007%
2/12/2021Credit Suisse AG93,906$13M0.0%+30.2%0.154%
2/12/2021CHI Advisors LLC3,000$0.42M0.1%-60.0%0.005%
2/12/2021Virtus ETF Advisers LLC3,972$0.55M0.2%-53.7%0.007%
2/12/2021Motley Fool Asset Management LLC55,336$7.66M0.6%+22.0%0.091%
2/11/2021Northern Trust Corp775,791$107.39M0.0%+4.5%1.271%
2/11/2021Public Employees Retirement Association of Colorado127,290$17.62M0.1%+1,322.9%0.209%
2/11/2021First Mercantile Trust Co.1,152$0.16M0.0%-9.6%0.002%
2/11/2021Barclays PLC23,524$3.26M0.0%-75.9%0.039%
2/11/2021Citigroup Inc.41,967$5.81M0.0%+594.8%0.069%
2/11/2021Teacher Retirement System of Texas5,134$0.71M0.0%+61.0%0.008%
2/11/2021Westpac Banking Corp43,471$6.02M0.1%+11.5%0.071%
2/11/2021RMB Capital Management LLC28,689$3.97M0.1%+1.9%0.047%
2/11/2021Dynamic Technology Lab Private Ltd1,817$0.25M0.0%N/A0.003%
2/11/2021Oppenheimer Asset Management Inc.2,498$0.35M0.0%-22.6%0.004%
2/11/2021Xponance Inc.1,838$0.25M0.0%N/A0.003%
2/10/2021Rhumbline Advisers85,203$11.80M0.0%+10.1%0.140%
2/10/2021Renaissance Technologies LLC94,800$13.12M0.0%N/A0.155%
2/10/2021Clearbridge Investments LLC1,875,317$259.60M0.2%+5.4%3.072%
2/10/2021QS Investors LLC3,834$0.53M0.0%-1.7%0.006%
2/10/2021Mckinley Capital Management LLC Delaware25,980$3.60M0.3%N/A0.043%
2/10/2021Harvest Fund Management Co. Ltd888$0.12M0.0%+15.9%0.001%
2/9/2021Wells Fargo & Company MN84,643$11.72M0.0%+105.2%0.139%
2/9/2021ClariVest Asset Management LLC30,365$4.20M0.1%-22.5%0.050%
2/9/2021Bank of New York Mellon Corp758,632$105.02M0.0%-1.8%1.243%
2/9/2021Illinois Municipal Retirement Fund2,640$0.37M0.0%+121.8%0.004%
2/9/2021CI Investments Inc.4,527$0.63M0.0%N/A0.007%
2/9/2021Mitsubishi UFJ Kokusai Asset Management Co. Ltd.2,112$0.29M0.0%-21.7%0.003%
2/9/2021ProShare Advisors LLC25,153$3.48M0.0%+41.3%0.041%
2/9/2021Profund Advisors LLC14,008$1.94M0.1%+20.7%0.023%
2/9/2021Great Lakes Advisors LLC140,286$19.42M0.4%N/A0.230%
2/8/2021Alliancebernstein L.P.1,187,569$164.40M0.1%-14.0%1.945%
2/8/2021State Board of Administration of Florida Retirement System25,845$3.58M0.0%-10.6%0.042%
2/8/2021New York State Common Retirement Fund147,806$20.46M0.0%+12.8%0.242%
2/8/2021Sei Investments Co.14,757$2.04M0.0%-36.0%0.024%
2/8/2021AGF Investments LLC180$25K0.0%N/A0.000%
2/8/2021Russell Investments Group Ltd.39,520$5.47M0.0%-2.9%0.065%
2/5/2021Tortoise Investment Management LLC945$0.13M0.0%-9.6%0.002%
2/5/2021BlackRock Inc.5,287,476$731.95M0.0%+9.9%8.662%
2/5/2021Aperio Group LLC16,791$2.32M0.0%+23.9%0.028%
2/5/2021Y Intercept Hong Kong Ltd3,169$0.46M0.2%N/A0.005%
2/5/2021Swiss National Bank130,152$18.02M0.0%+1.2%0.213%
2/5/2021SG Americas Securities LLC3,230$0.45M0.0%-22.7%0.005%
2/5/2021US Bancorp DE14,935$2.07M0.0%+253.9%0.024%
2/4/2021Los Angeles Capital Management LLC18,781$2.60M0.0%+0.5%0.028%
2/4/2021GSA Capital Partners LLP3,084$0.43M0.1%N/A0.005%
2/4/2021State of Wisconsin Investment Board87,000$12.04M0.0%-4.4%0.143%
2/3/2021CIBC Asset Management Inc2,254$0.31M0.0%N/A0.004%
2/3/2021State of New Jersey Common Pension Fund D38,055$5.27M0.0%-6.3%0.062%
2/2/2021California Public Employees Retirement System151,797$21.01M0.0%+26.6%0.249%
2/2/2021First Trust Advisors LP763,805$105.73M0.1%-18.5%1.251%
2/1/2021Victory Capital Management Inc.6,760$0.94M0.0%+43.2%0.011%
2/1/2021Assenagon Asset Management S.A.59,891$8.29M0.0%N/A0.098%
1/29/2021Emerald Mutual Fund Advisers Trust218,390$30.23M1.1%N/A0.358%
1/29/2021Emerald Advisers LLC226,875$31.41M1.0%N/A0.372%
1/28/2021Arizona State Retirement System16,693$2.31M0.0%-2.5%0.027%
1/28/2021Zurcher Kantonalbank Zurich Cantonalbank6,955$0.96M0.0%+13.6%0.011%
1/28/2021Dupont Capital Management Corp2,924$0.41M0.0%-7.0%0.005%
1/27/2021Calamos Advisors LLC9,648$1.34M0.0%N/A0.016%
1/27/2021JGP Global Gestao de Recursos Ltda.1,586$0.22M0.8%N/A0.003%
1/26/2021Pinnacle Associates Ltd.158,355$21.92M0.4%-5.6%0.259%
Data available starting January 2016

See Full Table
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $103.48
$101.15
$105.91

50 Day Range

MA: $124.29
$105.27
$148.14

52 Week Range

Now: $103.48
$51.73
$179.65

Volume

324,295 shs

Average Volume

459,911 shs

Market Capitalization

$6.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Who are the company insiders with the largest holdings of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's top insider shareholders include:
  1. Emil D Kakkis (CEO)
  2. Shalini Sharp (CFO)
  3. Thomas Richard Kassberg (EVP)
  4. William Aliski (Director)
  5. Matthew K Fust (Director)
  6. John Richard Pinion (Insider)
  7. Karah Herdman Parschauer (EVP)
  8. Theodore Alan Huizenga (SVP)
  9. Matthew K Fust (Director)
  10. Clay B Siegall (Director)
  11. Camille L Bedrosian (EVP)
  12. Emil D Kakkis (CEO)

Who are the major institutional investors of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's top institutional investors include:
  1. Pacer Advisors Inc. — 0.00%

Which major investors are selling Ultragenyx Pharmaceutical stock?

During the last quarter, RARE stock was sold by these institutional investors:
  1. Pacer Advisors Inc.
During the previous year, company insiders that have sold Ultragenyx Pharmaceutical company stock include:
  1. Emil D Kakkis (CEO)
  2. Shalini Sharp (CFO)
  3. Thomas Richard Kassberg (EVP)
  4. William Aliski (Director)
  5. Matthew K Fust (Director)
  6. John Richard Pinion (Insider)
  7. Karah Herdman Parschauer (EVP)
  8. Theodore Alan Huizenga (SVP)
  9. Matthew K Fust (Director)
  10. Clay B Siegall (Director)
  11. Camille L Bedrosian (EVP)
  12. Emil D Kakkis (CEO)
Emergency Briefing: “The Great Reset”
By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. Jeff Brown, a member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive.
Click here to see this emergency briefing before i